Innovative Platform Launch Cellply recently launched VivaCyte, an end-to-end single-cell potency characterization platform that integrates potency analysis and immunophenotyping, representing a strong value proposition for biotech and pharma companies focused on cell therapy R&D and quality control.

Growing Funding and Recognition With recent funding rounds totaling over $3.6 million and prestigious awards, Cellply demonstrates financial growth and industry validation, indicating increased capacity and potential for expanding customer engagement and strategic partnership opportunities.

Strong Market Focus Operating within the cell therapy and oncology sectors, Cellply’s specialized analytical tools and recent product launches position it well to serve biotech firms, clinical laboratories, and pharmaceutical companies seeking advanced single-cell analysis solutions.

Technological Edge Utilizing proprietary microfluidic and AI-powered analytics, Cellply offers highly-automated, precise, and scalable solutions, appealing to research institutions and biotechs aiming to accelerate immunotherapy development and improve process efficiency.

Emerging Global Presence Based in Italy with recent product launches and industry recognition, Cellply is positioned for international expansion, creating opportunities to establish partnerships with global research and commercial organizations focused on cell-based therapeutic innovations.